[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.40 2.93% 84.40 83.00 84.20 84.20 82.20 82.20 5,545,404 16:35:24
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 65.3 15.4 2.5 34.4 384

Ekf Diagnostics Share Discussion Threads

Showing 3676 to 3698 of 3900 messages
Chat Pages: 156  155  154  153  152  151  150  149  148  147  146  145  Older
DateSubjectAuthorDiscuss
06/7/2021
08:01
Apparently, later this week it will be announced that regular testing is expected to replace the disruptive self-isolation regime, and given the significant rise expected/forecast in infection rates over the next few months, testing volumes will likely increase accordingly......and probably significantly!
wan
02/7/2021
08:12
And as a reminder and to put the above into at least some context, from EKF's 2021 – 2024 Growth Strategy Investor Presentation w/c 7 June 2021 - 2. Exploit newly expanded capabilities to meet the demand for contract manufacturing services Leverage relationship with private sector partner to support their diagnostics strategy EKF currently makes kits for their COVID sample collection product in USA, UK and Germany Customer is the largest distribution business in the world Leveraging distribution business to move into ‘home diagnostics’ EKF perfect partner due to manufacturing capabilities in US, Europe and UK EKF also a key regulatory partner Collaborating on new molecular enzyme product to be made in Elkhart Reliant on EKF for all diagnostic advice Increasing demand for kit manufacturing Substantial revenue and EBITDA growth opportunity Page 8 - hTTps://www.ekfdiagnostics.com/res/EKF%20Investor%20Presentation%20June%202021%20Growth%20strategy%202021-2024.pdf
wan
01/7/2021
05:58
Staying with the attributes of PrimeStore MTM and the ability to rapidly detect SARS-CoV-2 and influenza virus infection from a single sample - Mark Weaver EKF Diagnostics Regional Sales Manager (Western Europe/ DACH) Great to see this publication. PrimeStore MTM is being used routinely with Roche LIAT systems in the NHS. This ensures viral RNA integrity which minimises false negative results and keeps NHS staff safe! Luke Daum • 3rd+ Chief Scientific Officer and Executive VP at Longhorn Vaccines and Diagnostics 13h • Edited • 13 hours ago Thrilled that my clinical research using Roche's cobas Liat for SARS-CoV-2 (#covid19research) is finally published in The Journal of Applied Laboratory Medicine (Oxford University Press) and available online here: hTTps://www.linkedin.com/posts/mark-weaver-9383855_covid19research-alamoheights-texas-activity-6816081337749925889-uw45 The Liat® is a multiplex system capable of simultaneous detection of SARS-CoV-2, and influenza A and B RNA from patient samples - Rapid and Safe Detection of SARS-CoV-2 and Influenza Virus RNA using Onsite qPCR Diagnostic Testing from Clinical Specimens Collected in Molecular Transport Medium Luke T Daum, Gerald W Fischer The Journal of Applied Laboratory Medicine, jfab073, hxxps://doi.org/10.1093/jalm/jfab073 Published: 22 June 2021 hTTps://academic.oup.com/jalm/advance-article/doi/10.1093/jalm/jfab073/6307725
wan
30/6/2021
08:55
Worth reading and keeping firmly in mind as the flu season approaches, that PrmeStore MTM enables testing for both COVID-19 and influenza from a single sample - PrimeStore® MTM An explanation of the differences between Molecular Transport Media and Viral Transport Media Summary The main difference between MTM and VTM is that molecular transport media, such as PrimeStore® MTM, will fully deactivate viruses, bacteria, fungi and mycobacterium tuberculosis, allowing safe sample handling and transport to greatly reduce infection risk. PrimeStore MTM is a FDA cleared and CE IVD marked infectious disease sample collection, storage and transport system which was specifically developed to overcome the short comings of standard viral transport media (VTM) and universal transport media (UTM) that do not inactivate microbes and can also inhibit molecular testing. In Conclusion The novel, patented sample collection device, PrimeStore® MTM allows COVID-19 samples to be rapidly inactivated in the collection tube. This immediately eliminates infection risk and also preserves nucleic acids for downstream molecular processing without need for refrigeration. In addition to removing the need for expensive cold chain transport and storage of samples, RNA and DNA are perfectly preserved by PrimeStore MTM for up to four weeks. This means that it is ready for safe testing immediately on arrival at a laboratory and without need for containment. In the case of COVID-19, this opens up options for more testing laboratories, making this device a key part of the testing supply chain which can underpin the safe and rapid increase of testing capacity. PrimeStore MTM is also being used during the coronavirus pandemic by a number of businesses to provide COVID-19 testing services for their staff. This is enabling them to bring back those who may be self-isolating due to concerns over infection, or that of a family member. The fact that it also enables laboratories to test for both COVID-19 and influenza from a single sample will also be greatly beneficial as the flu season approaches. hTTps://www.ekfdiagnostics.com/res/Differences%20between%20Molecular%20Transport%20Media%20and%20Viral%20Transport%20Media
wan
29/6/2021
08:03
Interesting and encouraging EKF comments in the above interview. I have already been looking (quite closely) at testing for diabetic Ketoacidosis, for which EKF already has a very strong position, but there is real potential for EKF to become the global leader in my view, perhaps especially so with the increasing use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, which apparently raises the risk for diabetic ketoacidosis. I am thus expecting further developments in the specific area of B-HB (perhaps even a tie-up with Renalytix and or its pharma partners?). hTTps://www.ekfdiagnostics.com/beta-hydroxybutyrate.html hTTps://www.ekfdiagnostics.com/diabetic-ketoacidosis-assay-collaboration-between-ortho-clinical-diagnostics-and-ekf-diagnostics.html CLIA waived point of care test - hTTps://www.ekfusa.com/analyzers/stat-site-wb/
wan
29/6/2021
06:58
https://www.voxmarkets.co.uk/articles/vox-markets-fund-manager-interview-with-chris-mills-d8a6ec6/
mirandaj
29/6/2021
05:22
Just in case you missed it yesterday. Marvellous insights from Christopher Mills of Harwood Capital - a world class investor - talking about top quality stocks, such as EKF Diagnostics. Heaven personified www.linkedin.com/posts/paul-hill-a5994116_vox-markets-fund-manager-interview-with-chris-activity-6815288599295123456-BgJJ
brummy_git
26/6/2021
06:04
Link added to above post (I forgot to include the link to the April news article, for comparison etc)
wan
25/6/2021
13:51
Great research Wan thanks
melody9999
25/6/2021
08:50
Interesting 'private sector' development - Readers may recall that back in April (as reported on here) that Amazon said that it was launching the next phase of its Amazon Web Services (AWS) Diagnostic Development Initiative, in which it plans to distribute $12 million this year to fund projects for SARS-CoV-2 testing, as well as for other infectious disease diagnostics. AWS also said it will prioritize COVID-19 projects but will also evaluate projects focused on other infectious diseases. The company will accept applications through the end of the year, with priority given to applications received before July 31. "We have seen transformative innovations in how we diagnose disease over the past year, from machine learning-powered X-ray imagery analysis to new developments in rapid, high quality, and direct-to-consumer tests," Vin Gupta, chief medical officer of Amazon's COVID-19 response unit, said in a statement. "These changes will continue to evolve and improve our ability to respond to future outbreaks. We have already seen inspirational results from the Diagnostic Development Initiative, and we look forward to supporting broader uses of cloud technologies to enable organizations and communities to identify and respond even faster to future outbreaks." hTTps://www.360dx.com/diagnostics/amazon-give-out-12m-under-next-phase-aws-diagnostics-development-initiative#.YNax2ehKiF5 It would appear that that initiative has indeed evolved, and I note that AWS has updated the initiative and increased the funds available to $20 million - The Amazon Web Services (AWS) Diagnostic Development Initiative (DDI) is a two-year, $20M commitment to accelerate research and innovation to advance the collective understanding and detection of COVID-19 and other infectious diseases in order to mitigate current and future outbreaks. AWS is offering AWS Promotional Credits and technical expertise to support the use of AWS services for projects by selected institutions and companies in four program areas: early disease detection, diagnostics, prognosis, and public health genomics. hTTps://aws.amazon.com/government-education/nonprofits/disaster-response/diagnostic-dev-initiative/
wan
23/6/2021
12:01
Mr Market not made its mind up yet on this bad boy. Practising extreme patience and biding my time before I get involved.
tongosti
23/6/2021
08:49
The article below follows up on the news that I previously posted regarding AWS. Suffice to say that as an EKF investor, and with digital innovation fast becoming the next frontier in healthcare, I am very pleased and encouraged that EKF's management have their fingers on the pulse, investing accordingly (spinouts included) and demonstrating that EKF is very relevant now and into the future - Jun 22, 2021 Amazon Continues Its Bold Expansion Into Healthcare, As AWS Launches A New Healthcare Accelerator Furthermore, AWS’ initiative is by no means a new frontier for Amazon. In fact, Amazon has increasingly been venturing into the healthcare space, indicating its interest in potentially becoming a key market player in the industry one day. One significant example is Amazon Care, a relatively new virtual care platform aiming to provide patients with comprehensive care. The platform explains that in addition to enabling real-time access to clinicians, “nurses will come directly to you for testing, immunizations, blood draws, and more,” and that the service will “deliver Amazon Care prescribed medications right to your door.” Indeed, if history indicates any relevant marker of success, Amazon’s attempt to enter the rapidly growing digital care market could potentially be an industry game-changer. Ultimately, this new initiative by AWS provides renewed perspective that digital innovation is the next frontier in healthcare. Undoubtedly, companies, organizations, and government entities must invest in and prioritize these initiatives if there is any hope of continuing to stay relevant in healthcare in the years to come. hTTps://www.forbes.com/sites/saibala/2021/06/22/amazon-continues-its-bold-expansion-into-healthcare-as-aws-launches-a-new-healthcare-accelerator/ Everyday Care Now Available: Primary And Preventive Care Services hTTps://amazon.care/health-stories/primary-and-preventive-care
wan
23/6/2021
07:55
I note from EKF's FY Presentation that EKF secured agreements with two reference labs to add Glycated Albumin to their portfolio.
wan
23/6/2021
07:49
The Lucica® glycated albumin test is distributed exclusively by EKF USA. hTTps://www.ekfusa.com/chemistry_range/lucica-glycated-albumin-l-glycemic-control-marker/ EKF are exhibiting at the 81st Scientific Sessions Event by American Diabetes Association Jun 25, 2021, 3:00 PM - Jun 29, 2021, 9:00 PM - EKF introduces 3 new products to our expanding diabetes test portfolio: Glycated Albumin, STAT-Site® WB for clinical use and BIOSEN-R for research use. The Lucica® method for Glycated Albumin (GA), manufactured by Asahi Kasei Pharma Corporation, is a specific enzymatic test for GA that is now FDA cleared for sale in the U.S. The Lucica® test is distributed exclusively by EKF USA. The Lucica® test is one of the most widely used and published GA methods worldwide. Lucica® Glycated Albumin-L can fill the gap between long-term and short-term glycemic control markers. The STAT-Site® WB Dual Analyte Measurement System from EKF Diagnostics is used for the quantitative determination of β-ketones (Beta-Hydroxybutyrate or βHB) and glucose in capillary and venous blood. The STAT-Site® WB is intended for whole blood multiple-patient use in professional healthcare settings as an aid to monitor the effectiveness of a diabetes control program. BIOSEN-R is a dual channel, bench top analyzer for lactate and glucose measurements for research lab use (RUO). The measurement principle is enzymatic-amperometric and can measure glucose and lactate in a variety of sample types, including venous, arterial and capillary blood, plasma, serum, fermentation broth, cell culture media. hTTps://eventpilot.us/web/planner.php?id=ADA21
wan
22/6/2021
08:13
Given Julian Baines new role, which will focus on delivering further value from the Company’s relationship with Mount Sinai Innovation Partners (“MSIP”), I found the following recent news items quite interesting, although any direct relevance to EKF of course remains to be seen - New York, NY (June 08, 2021) Mount Sinai Innovation Partners (MSIP), the commercialization engine of the Mount Sinai Health System (Mount Sinai) in New York City, has launched Elementa Labs, a virtual incubator program that aims to position health care and biotechnology startup companies for the next stage in their development. The program empowers companies to strategically align with Mount Sinai, gaining access to subject matter experts in health care and the potential to advance their core technology platforms. Participating companies will work directly with a Mount Sinai champion who will facilitate navigation within the Health System and enable access to key stakeholders, resources, and know-how to advance product development. “Elementa Labs will integrate Mount Sinai’s research and clinical expertise with the business and product development infrastructure of health care startup companies,” said Erik Lium, PhD, President of MSIP and Chief Commercial Innovation Officer of Mount Sinai Health System. “We look forward to engaging with entrepreneurs to bring health care innovations to the patient population.” hTTps://www.mountsinai.org/about/newsroom/2021/mount-sinai-health-system-launches-elementa-labs-a-virtual-incubator-program I found the following Amazon Web Services announcement quite interesting too - AWS Public Sector Blog AWS announces AWS Healthcare Accelerator for startups in the public sector by Sandy Carter | on 21 JUN 2021 The healthcare industry is currently experiencing seismic shifts with much of the focus being placed on COVID-19 clinical, operational, and financial efforts. However, even in the setting of the pandemic, the healthcare industry is still faced with addressing a growing aging population, a widening workforce gap, and a proliferating volume of healthcare data. Healthcare organizations, from hospital systems to public health agencies, have been turning to technology solutions to help them quickly adapt and respond to these challenges and rapidly innovate with data-driven and compliant solutions. To support both high-potential healthcare startups and the healthcare industry need for innovative solutions, we are excited to announce the launch of the Amazon Web Services (AWS) Healthcare Accelerator program. Full release - hTTps://aws.amazon.com/blogs/publicsector/aws-announces-healthcare-accelerator-program-startups-public-sector/
wan
21/6/2021
09:29
Coming onto radars? Most readers will know that EKF and Kantaro Biosciences partnered to market quantitative COVID antibody testing in UK and Europe. The Kantaro COVID-SeroKlir kit is a direct ELISA for the quantitative detection of human IgG antibodies to the SARS-CoV-2 virus in serum and plasma (K2-EDTA/Li-Heparin) samples. COVID-SeroKlir has FDA Emergency Use Authorization (EUA) in November 2020 having previously received a CE mark in October 2020. COVID-SeroKlir has demonstrated 97.8% sensitivity and 99.6% specificity for detecting SARS-CoV-2 specific IgG antibodies against two virus antigens, the full-length spike protein and its receptor-binding domain. COVID-SeroKlir is a two-step enzyme-linked immunosorbent assay (ELISA) and can be used by any certified laboratory* without the need for proprietary equipment. hTTps://www.ekfdiagnostics.com/COVID-SeroKlir.html Given the success and indeed acceleration in vaccinating populations, the conversation is perhaps changing in terms of the need to determine the level of immunity (conferred by infection or vaccination), but perhaps more importantly for how long that immunity lasts i.e. do we need booster jabs, or perhaps more to the point, when. The following provides for an interesting read - Why Antibody Testing Should Be Our Next Tool in the Fight Against COVID-19 June 15 2021 Keir Lewis hTTps://www.technologynetworks.com/diagnostics/articles/why-antibody-testing-should-be-our-next-tool-in-the-fight-against-covid-19-349815
wan
21/6/2021
09:26
Personally speaking, I am looking forward to point of care tests that will effectively obsolete the Innova test, rather than wait for the governments efforts to support and justify their massive purchase and use of the Innova lateral flow tests (including sprinkling them about like confetti in order to use up the stock of millions!). Time will tell, but I believe heads deserve to fall! Off some radars? Staying with rapid point of care tests (that will almost certainly not be limited to Covid-19), and just as a reminder, let's not forget about PrimeStore ATM. Tests are emerging and commercially launching that do not require separate nucleic acid extraction or purification, such tests utilise a procedure that involves collecting an anterior nasal swab or nasopharyngeal swab sample which is eluted directly into the tests vial containing 'Extraction Buffer'. That extraction buffer is not a simple PBS in my view (which is suitable for many other tests/applications). Another reminder - PrimeStore® ATM is a virucidal, bacteriostatic, Guanidine-free sample collection device, offering highly sensitive antigen testing capabilities. An initial EUA using PrimeStore® ATM was filed in early September. hTTps://lhnvd.com/primestore-atm I have said this previously, referring to FDA EUA 'using' ATM, implies that it was filed in September as 'part' of a test (or tests) i.e. perhaps as a solution that's already in the test vials. So, again time will tell if ATM forms an integral part of 'antigen' tests generally, or is perhaps quite specific to a particular platform (initially as an EUA?).
wan
18/6/2021
18:47
You could say I’m sensible ;) and likewise have a good weekend
senseibull
18/6/2021
18:43
We have all started as a novice and there is always something new to learn in this game no matter how long one has been in this game for. I wish you well with your efforts and if you allow me one piece of advice - that would be that the one thing worth spending time on is to learn to aggressively manage risk. 99% don't (including professional portfolio managers) and that's why they end in trouble. Enjoy your weekend.
tongosti
18/6/2021
18:37
@tongosti I’m still a novice but I think your opinion is correct on this one.
senseibull
18/6/2021
18:35
As for the number of trades the very best in the business (those who produce +300% years) trade anything from 10 to 30 times a day. I am not one of those very high number of trades guy but the point is the fact you don't get it, it means just that. That YOU don't get it!
tongosti
18/6/2021
18:32
That's precisely why there are so many ways to skin the cat in this game. My forte is numbers. Yours is something else. As long as it works for you I am happy that you are happy. That's what makes markets
tongosti
18/6/2021
17:50
I don't either, but tong does!
jacks13
Chat Pages: 156  155  154  153  152  151  150  149  148  147  146  145  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210928 23:55:52